A longitudinal, epigenome-wide study of DNA methylation in anorexia nervosa: results in actively ill, partially weight-restored, long-term remitted and non-eating-disordered women

Howard Steiger, PhD*; Linda Booij, PhD*; Esther Kahan, BSc; Kevin McGregor, MSc; Lea Thaler, PhD; Emilie Fletcher, BA; Aurelie Labbe, PhD; Ridha Joobar, MD, PhD; Mimi Israël, MD; Moshe Szyf, PhD; Luis B. Agellon, PhD; Lise Gauvin, PhD; Annie St-Hilaire, PhD; Erika Rossi, MA

Introduction

Anorexia nervosa can devastate medical, psychological and social adjustments, and despite treatment advances, only about half of people with the condition achieve full remission after 10 or more years. Such realities point to the need for improved knowledge of the causal and maintaining factors of what can be an insidious disorder.

Anorexia nervosa is understood to have multiple determinants, including genetic factors (shaping such processes as emotion regulation, reward sensitivity and energy metabolism), environmental triggers (including perinatal, developmental and later-life events), state-related effects (owing to nutritional and mental status) and social inducements toward intensive caloric restraint. Although twin studies have shown anorexia nervosa to be strongly heritable, efforts to identify syndrome-relevant genes have been disappointing. However, a recent study has documented a genetic locus that reached genome-wide significance for anorexia nervosa: a site on chromosome 12 associated with type 1 diabetes and autoimmune diseases. Genetic correlations associated anorexia nervosa with both mental-illness (schizophrenia and neuroticism) and metabolic (glucose and lipid metabolism) phenotypes. In other words, broad
psiatic, metabolic and autoimmune spheres have been indicated.

Gene–environment interactions and epigenetics

Complex psychiatric syndromes are almost certain to involve the environmental activation of hereditary potentials, and this likely applies to anorexia nervosa: risk of anorexia nervosa is increased when people who are genetically predisposed experience familial distress. Likewise, animal data suggest that genetic susceptibility, combined with adolescent social stress and caloric restraint, produces a mouse analog to anorexia nervosa: mice that let themselves starve. Diverse environmental influences have been postulated to act in anorexia nervosa, including obstetric insults, gestational stress, childhood trauma, familial conflict and social induction toward caloric restraint. Epigenetic processes influence gene expression and corresponding phenotypic variations. Some epigenetic mechanisms appear to be environmentally responsive and constitute plausible substrates for gene–environment interactions that underlie mental-illness phenotypes, including anorexia nervosa. The best-studied epigenetic mechanism is DNA methylation, which generally reduces gene expression. Research has shown that DNA methylation responds to perinatal insults and early-life stresses and is also influenced by psychotherapeutic, nutritional and pharmacologic interventions. If so, DNA methylation could be a marker of disease staging or therapeutic response.

DNA methylation in anorexia nervosa

An accumulating literature has associated anorexia nervosa with altered DNA methylation. Candidate-gene studies have linked anorexia nervosa to hypermethylation of genes for α-synuclein (involved in neurotransmitter release), natriuretic peptide (implicated in anxiety, depression and stress responses), dopamine function (implicated in reward sensitivity and binge-eating) and oxytocin (linked to attachment). Other studies in anorexia nervosa have estimated global DNA methylation levels, although they have been limited by small samples or methods that interrogate narrow genomic regions. One study, using DNA from peripheral blood obtained from 10 women with anorexia nervosa and 10 without, found no differences when comparing methylation of LINE1 repetitive elements (a proxy for global methylation). Two other studies, involving 22 adults with anorexia nervosa (subtype unspecified) and another involving 32 adolescents with anorexia nervosa, restricting type, reported lower global methylation; the first used a nonradioactive elongation assay, the second involved incorporation of [3H]dCTP following a cut with HpaII.

Because global methylation measures provide a rather blunt indicator of possible epigenetic effects, gene-specific methylation differences assessed using microarray technologies are likely to be more informative. We recently used a high-throughput technology (Infinium Human Methylation 450 BeadChip Kit; Illumina Inc.) and DNA in leukocytes from 29 women with anorexia nervosa and 15 women without anorexia nervosa and within a healthy weight range to perform a genome-wide examination of methylation levels. Case-control comparisons with false discovery rate (FDR) corrections identified 14 differentially methylated CpG probes, corresponding to genes acting in histone acetylation, cholesterol storage, lipid transport and dopamine and glutamate signalling. Findings also linked the chronicity of illness to methylation at 119 genes associated with anxiety, social behaviour, immunity and nervous-system function. In other words, like the genome-wide association study described earlier, our study indicated altered psychiatric, physiologic and immune functions. A subsequent independent study using the same technology compared DNA methylation in 47 women with anorexia nervosa to 100 population-based controls and identified 81 differentially methylated sites. Both studies isolated the NR1H3 gene (involved in lipid homeostasis and inflammation) and the TNXB gene (associated with connective-tissue disorders).

Present study

We extended our investigation of DNA methylation in people with and without anorexia nervosa, increasing sample sizes and adding a sample of women who, when tested, had been free of eating-disorder symptoms and weight-restored for at least 1 year. We also investigated within-subject longitudinal changes in methylation levels (attributable to stabilization of symptoms and weight restoration). Our combined prospective/cross-sectional design was intended to help differentiate transient illness sequelae from stable epigenetic traits.

Methods

Procedures in this study complied with the ethical standards of relevant institutional committees and the Helsinki Declaration, revised in 2008.

Participants

Participants with an active eating disorder (active group), recruited at a specialized eating disorders program, included 75 women with an anorexia nervosa diagnosis according to DSM-5 and a body mass index (BMI) under 18 kg/m². Of these, 34 had anorexia nervosa restrictive type and 41 had anorexia nervosa binge/purge type. Of the total, 29 figured in our earlier report (see Booij and colleagues). Diagnoses were based on interviews with the Eating Disorders Examination (EDE) or clinical interviews conducted by specialist clinicians, complemented by results from the EDE Questionnaire (EDE-Q; 4 cases). We obtained follow-up methylation and clinical data on 52 women (28 with anorexia nervosa restrictive type and 24 with anorexia nervosa binge/purge type) after an average of 114 days (range 62 to 182 days) of treatment emphasizing weight restoration.

We also recruited 31 women who had previously fulfilled the DSM-5 criteria for anorexia nervosa but who, upon entry into the study, did not meet criteria for anorexia nervosa or...
bulimia nervosa (based on retrospective EDE interviews), and had maintained a self-reported BMI of 18 kg/m² or higher for at least 12 months (remitted group).

Excluding people taking medications was impractical and undesirable on grounds of representativeness, so we retained 51 of 75 women (68.0%) in the active group and 10 of 31 women (32.3%) in the remitted group who were taking psychoactive medication. We also retained participants who had mood, anxiety, substance use or personality disorders, but not conditions that would create interpretive confounds (e.g., endocrinologic, diabetic, neoplastic or cardiovascular diseases; substance dependence, psychosis or bipolar illness).

Details of participants’ BMI, age, illness characteristics, medication use and cigarette smoking are provided in Table 1. Groups did not vary according to mean age, but did differ as expected in terms of mean BMI and EDE total scores. The 2 active anorexia nervosa groups showed significantly lower BMI and had significantly more eating disorder symptoms than the other 2 groups did. Compatible with known differences with respect to the prevalence of cigarette smoking,30 participants with anorexia nervosa binge/purge type were significantly more likely to smoke than members of other groups were (Table 1). We controlled statistically for effects attributable to age and smoking. However, variations related to comorbidity, substance use and medication type rendered application of meaningful statistical controls unrealistic.

We recruited 41 non-eating-disordered (NED) women through public and university-/college-based announcements. These women showed no eating disorder or other psychiatric illnesses according to structured interviews. None of the women in the NED group used psychoactive medications. Data for 15 of the women in the NED group were included in our earlier report.26

### Table 1: Participant characteristics, medication use, psychiatric comorbidity and habits

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Active, anorexia nervosa restriet type (n = 34)</th>
<th>Active, anorexia nervosa binge/purge type (n = 41)</th>
<th>NED (n = 41)</th>
<th>Remitted (n = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI*</td>
<td>14.39 ± 1.72 (10.80–17.54)</td>
<td>15.78 ± 1.20 (13.09–17.81)</td>
<td>22.55 ± 2.38 (18.31–29.00)</td>
<td>21.10 ± 2.02 (18.43–25.43)</td>
</tr>
<tr>
<td>Age†</td>
<td>24.88 ± 8.39 (18–53)</td>
<td>23.41 ± 5.28 (18–43)</td>
<td>23.93 ± 5.33 (18–40)</td>
<td>26.81 ± 5.41 (19–38)</td>
</tr>
<tr>
<td>Chronicity, mo‡</td>
<td>96.00 ± 98.91 (12–456)</td>
<td>78.44 ± 57.68 (12–192)</td>
<td>NA</td>
<td>84.39 ± 44.31 (12–216)</td>
</tr>
<tr>
<td>EDE-Q total score§</td>
<td>3.19 ± 1.10 (1.14–5.40)</td>
<td>4.20 ± 1.09 (1.09–5.59)</td>
<td>0.32 ± 0.31 (0.00–1.39)</td>
<td>0.92 ± 0.83 (0.05–2.68)</td>
</tr>
<tr>
<td>Medication use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antidepressants</td>
<td>16 (47.06)</td>
<td>21 (51.22)</td>
<td>0</td>
<td>8 (25.81)</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>9 (26.47)</td>
<td>11 (26.83)</td>
<td>0</td>
<td>2 (6.45)</td>
</tr>
<tr>
<td>Hypnotics</td>
<td>1 (2.94)</td>
<td>2 (4.88)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anxiolytics</td>
<td>6 (17.65)</td>
<td>4 (9.76)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mood stabilizers</td>
<td>0</td>
<td>1 (2.44)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Psychiatric comorbidity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major depressive episode</td>
<td>4 (11.76)</td>
<td>15 (36.59)</td>
<td>0</td>
<td>2 (6.45)</td>
</tr>
<tr>
<td>Dysthymia</td>
<td>2 (5.88)</td>
<td>1 (2.44)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Panic disorder</td>
<td>1 (2.94)</td>
<td>0</td>
<td>0</td>
<td>2 (6.45)</td>
</tr>
<tr>
<td>Panic disorder with agoraphobia</td>
<td>2 (5.88)</td>
<td>2 (4.88)</td>
<td>0</td>
<td>1 (3.23)</td>
</tr>
<tr>
<td>Agoraphobia without panic disorder</td>
<td>0</td>
<td>1 (2.44)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Social anxiety disorder</td>
<td>1 (2.94)</td>
<td>5 (12.20)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Specific phobia</td>
<td>2 (5.88)</td>
<td>4 (9.76)</td>
<td>0</td>
<td>1 (3.23)</td>
</tr>
<tr>
<td>Generalized anxiety disorder</td>
<td>9 (26.47)</td>
<td>8 (19.51)</td>
<td>0</td>
<td>3 (9.68)</td>
</tr>
<tr>
<td>Obsessive–compulsive disorder</td>
<td>2 (5.88)</td>
<td>2 (4.88)</td>
<td>0</td>
<td>1 (3.23)</td>
</tr>
<tr>
<td>Posttraumatic stress disorder</td>
<td>0</td>
<td>2 (4.88)</td>
<td>0</td>
<td>1 (3.23)</td>
</tr>
<tr>
<td>Obsessive–compulsive personality disorder</td>
<td>11 (32.35)</td>
<td>9 (21.95)</td>
<td>0</td>
<td>1 (3.23)</td>
</tr>
<tr>
<td>Borderline personality disorder</td>
<td>1 (2.94)</td>
<td>2 (4.88)</td>
<td>0</td>
<td>1 (3.23)</td>
</tr>
<tr>
<td>Cigarette smoker¶</td>
<td>2 (5.88)</td>
<td>12 (29.27)</td>
<td>5 (12.20)</td>
<td>3 (9.68)</td>
</tr>
</tbody>
</table>

BMI = body mass index; EDE-Q = Eating Disorder Examination Questionnaire; NA = not applicable; NED = non-eating-disordered; NS = not significant; SD = standard deviation.

*F*3,143 = 166.29, *p < 0.05.
†F*3,143 = 2.0, NS.
‡F*2,101 = 0.57, NS.
§F*3,127 = 148.89, *p < 0.05.
¶χ*2 = 9.20, *p < 0.05.
Clinical measures

We assessed eating-disorder symptoms using the EDE interview and/or the EDE-Q. The EDE is a gold-standard interview for assessing anorexic and bulimic symptoms (Cronbach α = 0.67–0.90). The EDE-Q is a 41-item self-report questionnaire based on the EDE (α = 0.78–0.93); EDE-Q results correspond well to those of the EDE. To estimate chronicity of illness (i.e., time since the onset of clinically significant symptoms of an eating disorder), trained interviewers established a retrospective portrait of each participant’s eating-symptom history and, in reference to EDE diagnostic items, estimated the point at which symptoms became severe enough to support a diagnosis based on DSM-5 criteria. We used anthropometric measures to compute participants’ BMI.

Because we started this study before the release of structured interviews based on DSM-5, we evaluated psychiatric comorbidity using the Structured Clinical Interview for DSM-IV (SCID-I) and the Structured Clinical Interview for DSM-IV Axis II (SCID-II) modules for borderline personality disorder and obsessive–compulsive disorder. However, we updated diagnostic determinations using DSM-5 criteria. During study recruitment, we conducted inter-rater reliability checks on diagnostic determinations in 25 pseudo-randomly chosen interview pairs. Those checks yielded prevalence-adjusted, bias-adjusted χ coefficients (used for imbalanced distribution of marginal cell totals) of 0.84 to 1, and percent agreements of 92% to 100% (Appendix 1, Table S1, available at jpn.ca/170242).

Genome-wide DNA methylation analyses

We collected whole blood in EDTA tubes and extracted DNA from leukocytes using a DNA extraction kit (Qiagen). Epigenome-wide analyses were conducted at the Genome Quebec Innovation Centre using the Infinium Human Methylation 450 BeadChip Kit (Illumina Inc.; n = 171 samples) or the Infinium MethylationEPIC BeadChip Kit (Illumina Inc.; n = 28 samples). Analyses were performed according to standard procedures, except that single-base extension and staining was automated. Samples from the 2 arrays were merged using the combineArrays function in minfi (Bioconductor). The reason different methylation array kits were used was that Illumina discontinued the 450 BeadChip kit. However, manufacturer information and an independent study suggest that samples can be combined across kits. Isolated DNA was first checked for quality with picogreen, and then bisulfite-converted using the EZ-96 DNA Methylation-Gold Kit (Zymo Research). Next, samples were transferred to BCD and then MSA4 plates, and neutralized before overnight amplification. The MSA4 plates were fragmented, precipitated and resuspended before hybridization and transfer to Multi BeadChips. The Multi BeadChips then underwent washing, single-base extension and staining before imaging using the HiScan array scanner (Illumina Inc.).

Data processing and data filtering

We processed raw data using R (Bioconductor). We performed quality control using minfi metrics. Functional normalization was applied and values were background-corrected. Primary outcome measures were β values at each probe, representing the proportion of methylated cells. The specific chromosomal position and associated gene for each probe were defined using manifest files from Illumina (https://support.illumina.com/downloads/humanmethylation450_15017482_v1–2_product_files.ilmn). To correct for cell-type distribution effects, we applied a statistical correction based on the reference methylation profiles of separated peripheral blood mononuclear cells.

The initial data set consisted of 453,093 probes obtained from 147 participants. Because all participants were female, we ignored probes located on the Y chromosome. To remove random technical variations, we retained only CpGs that were associated with known protein-coding genes and with a > 5% deviation in methylation. After functional normalization, we observed possible probe-wise batch effects (i.e., β values for some probes on a given plate fell far outside the range of β values on all other plates). To eliminate such cases, we removed probes with at least 1 value below the estimated 0.01st percentile or above the estimated 99.99th percentile of the samples on the remaining plates. The final data set for subgroup comparisons and chronicity analyses included 35,513 probes (7.8% of the original probes). The final data set for pre/post comparisons included 37,507 probes (8.2% of the original probes).

We compared groups based on descriptive and clinical variables using χ² or 1-way analysis of variance (ANOVA) as appropriate, performed with SPSS 23 (SPSS Inc.). We conducted methylation analyses using R. We conducted group comparisons at individual probes using linear models, with methylation level as the dependent variable, group as the independent variable and estimated cell proportions as covariates. We first tested for overall differences among groups (active versus remitted versus NED; anorexia nervosa restrictive type versus anorexia nervosa binge/purge type versus NED) using ANOVA, followed by pairwise comparisons where overall effects were significant. We repeated group comparisons with covariates that controlled for age variations and the presence or absence of cigarette smoking. Rare changes in significance levels resulting from application of covariates are annotated in the text and in Table 2. To examine associations between chronicity and methylation in the active sample, we used linear regression analysis. We used quantile regression to model the effects of median pre-/post-treatment differences in BMI on pre/post changes in probe-wise methylation levels, with the estimated cell-type proportions as a covariate. Quantile regression allowed for the comparison of findings in participants who had achieved substantial pre/post weight gain to those who had not. We applied FDR corrections within each set of analyses (i.e., within ANOVAs, analyses of covariance, pairwise contrasts, linear regression and quantile regression).
Results

Active versus remitted versus NED

A 1-way ANOVA for 3 groups showed differential methylation (at $Q < 0.01$) on 373 probes (representing 349 genes). For 295 of these (representing 277 genes), we found at least 1 significant pairwise comparison (at $Q < 0.01$). The ANOVA and pairwise comparison results for these 295 probes, ranked in order of statistical significance in the ANOVA, can be found in Appendix 1, Table S2.

Pairwise comparisons between the active and NED groups revealed 58 differentially methylated sites ($Q < 0.01$), corresponding to 55 genes. Some of the identified genes were linked to nutrition: for example, lipid processing ($PRKAG2$ [2 probes], $SCARF1$) and glucose metabolism ($RPTOR$ [2 probes], $SORBS1$). Others were relevant to bone health ($MICAL2$) and immune function ($FCGR2A$, $NOD1$). One gene was positively associated with serotonin 2B receptor function ($HTR2B$). According to $\beta$ values, methylation levels on 53 (91.4%) of the differentially methylated probes were higher in the active group, implying generally reduced expression of implicated genes in anorexia nervosa.

Pairwise comparisons between the active and remitted groups revealed 265 differentially methylated probes ($Q < 0.01$), corresponding to 252 genes (Appendix 1, Table S2). Similar to the active versus NED comparisons, many differentially methylated probes were linked to genes related to

Table 2: Probes and genes that overlapped between active versus NED and active versus remitted comparisons

<table>
<thead>
<tr>
<th>CpG</th>
<th>Gene</th>
<th>Description</th>
<th>Overall ANOVA</th>
<th>Active v. NED</th>
<th>Active v. remitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>cg04042861</td>
<td>HTR2B</td>
<td>Serotonin system</td>
<td>8.66E-07</td>
<td>0.00760</td>
<td>8.47E-07</td>
</tr>
<tr>
<td>cg09686816</td>
<td>CUEDC1</td>
<td>Glutamate concentration in brain</td>
<td>2.94E-05</td>
<td>0.00375</td>
<td>0.000785</td>
</tr>
<tr>
<td>cg00129811</td>
<td>DSE</td>
<td>Ehler-Danlos syndrome</td>
<td>0.000310</td>
<td>0.00597</td>
<td>0.00239</td>
</tr>
<tr>
<td>cg06350097</td>
<td>FCGR2A</td>
<td>Immune function; ulcerative colitis; rheumatoid arthritis; systemic lupus erythematosis</td>
<td>0.000128</td>
<td>0.00375</td>
<td>0.00653*</td>
</tr>
<tr>
<td>cg24101945</td>
<td>HFM1</td>
<td>Ovarian insufficiency; genome integrity in germ line</td>
<td>9.12E-05</td>
<td>0.00941</td>
<td>0.000122</td>
</tr>
<tr>
<td>cg14666404</td>
<td>MCF2L2</td>
<td>Polycystic ovary syndrome</td>
<td>6.90E-05</td>
<td>0.00334</td>
<td>0.000488</td>
</tr>
<tr>
<td>cg27631389</td>
<td>MICAL2</td>
<td>Bone health</td>
<td>7.43E-05</td>
<td>0.00781</td>
<td>0.000201</td>
</tr>
<tr>
<td>cg18734096</td>
<td>NOSIP</td>
<td>Nitric oxide synthesis; enterocolitis</td>
<td>2.94E-05</td>
<td>0.006645</td>
<td>0.00236</td>
</tr>
<tr>
<td>cg17272549</td>
<td>ELM6</td>
<td>Refractive astigmatism</td>
<td>3.17E-07</td>
<td>1.29E-06</td>
<td>1.11E-05</td>
</tr>
<tr>
<td>cg01423695</td>
<td>PRKAG2</td>
<td>Lipid metabolism; cholesterol biosynthesis</td>
<td>0.000132</td>
<td>0.00552</td>
<td>0.00128</td>
</tr>
<tr>
<td>cg22091236</td>
<td>RPTOR</td>
<td>Response to nutrient and insulin levels</td>
<td>0.000268</td>
<td>0.00707</td>
<td>0.00369</td>
</tr>
<tr>
<td>cg23011194</td>
<td>SORBS1</td>
<td>Insulin signalling</td>
<td>1.03E-05</td>
<td>0.00933</td>
<td>3.69E-06</td>
</tr>
<tr>
<td>cg08106319</td>
<td>ZFAND3</td>
<td>Insulin resistance; diabetes</td>
<td>1.19E-05</td>
<td>0.00963</td>
<td>3.57E-05</td>
</tr>
<tr>
<td>cg00323842</td>
<td>ZNF808</td>
<td>BMI; visceral fat</td>
<td>3.17E-07</td>
<td>8.32E-05</td>
<td>3.52E-05</td>
</tr>
<tr>
<td>cg10095247</td>
<td>ANKIB1</td>
<td>Cellular activity</td>
<td>0.00201</td>
<td>0.00933*</td>
<td>0.00867*</td>
</tr>
<tr>
<td>cg09144769</td>
<td>AP2B1</td>
<td>Protein transport</td>
<td>0.00108</td>
<td>0.00941*</td>
<td>0.00888*</td>
</tr>
<tr>
<td>cg20124877</td>
<td>KPNA1</td>
<td>Nuclear protein import</td>
<td>4.76E-05</td>
<td>0.00552</td>
<td>0.000129</td>
</tr>
<tr>
<td>cg15278374</td>
<td>GPR133</td>
<td>Cellular activity</td>
<td>0.000852</td>
<td>0.00645</td>
<td>0.00545</td>
</tr>
<tr>
<td>cg12872357</td>
<td>RAB32</td>
<td>Mitochondrial fission</td>
<td>0.000397</td>
<td>0.00570</td>
<td>0.00110</td>
</tr>
<tr>
<td>cg25292261</td>
<td>SNX27</td>
<td>Protein transport</td>
<td>0.000840</td>
<td>0.00462</td>
<td>0.00647*</td>
</tr>
<tr>
<td>cg08255475</td>
<td>CDT1</td>
<td>DNA replication</td>
<td>2.75E-05</td>
<td>0.00386</td>
<td>0.000292</td>
</tr>
<tr>
<td>cg19161559</td>
<td>CUX1</td>
<td>Gene expression; antidepressant response</td>
<td>0.000752</td>
<td>0.00954*</td>
<td>0.00404</td>
</tr>
<tr>
<td>cg14422240</td>
<td>FTSJD2</td>
<td>Methyltransferase</td>
<td>2.16E-06</td>
<td>9.33E-05</td>
<td>0.000609</td>
</tr>
<tr>
<td>cg03233624</td>
<td>MS12</td>
<td>Transcriptional regulation</td>
<td>1.98E-05</td>
<td>0.000553</td>
<td>9.12E-05</td>
</tr>
<tr>
<td>cg25197194</td>
<td>CCDC48</td>
<td>—</td>
<td>2.70E-06</td>
<td>0.00194</td>
<td>0.000109</td>
</tr>
<tr>
<td>cg01810593</td>
<td>KIAA1967</td>
<td>—</td>
<td>0.002261</td>
<td>0.00230</td>
<td>0.00649</td>
</tr>
<tr>
<td>cg18071202</td>
<td>LOC100292680</td>
<td>—</td>
<td>0.000343</td>
<td>0.00933</td>
<td>0.00236</td>
</tr>
<tr>
<td>cg06983052</td>
<td>LRRCS8D</td>
<td>—</td>
<td>8.66E-07</td>
<td>8.32E-05</td>
<td>0.000141</td>
</tr>
</tbody>
</table>

ANOVA = analysis of variance; BMI = body mass index; NED = non-eating-disordered.

*Gene functions and/or associated phenotypes are obtained using the National Center for Biotechnology Information gene database. Empty cells indicate genes on which clear functions are not listed. (See Appendix 1, Table S2, available at jpn.ca/170242, for full details of effect sizes and significance levels).

*$p < 0.05$ on a probe-wise comparison after adjustment for age and smoking. Significance level is otherwise $p < 0.01$ when the same covariates are applied.
genes have been associated with disorder-relevant functions.

Information gene database. Among these, we noted 2 genes relevant to psychiatric status or neurotransmitter function (HTR2B, CUEDC1); others associated with physiologic or immune functions (DSE, FCGR2A, HFM1, MCF2L2, MICAL2, NOSIP, EML6); others with functions linked to nutritional status, insulin activity or energy metabolism (PRKAG2, RPTOR, SORBS1, ZFAND3, ZNF608); and a remainder associated with more general cellular or transcriptional processes (ANKIB1, AP2B1, KPNA1, GPR133, RAB32, SNX27, CDT1, CLU1, FTSJD2, MS12). Note the observed connection between DSE and FCRA2 and Ehler-Danlos and autoimmune syndromes, respectively. Associations between anorexia nervosa and Ehler-Danlos,37 rheumatoid arthritis and systemic lupus erythematosus38 have been documented elsewhere.

**Anorexia nervosa restrictive type versus anorexia nervosa binge/purge type versus NED**

The results from 1-way ANOVAs comparing probe-wise methylation levels for anorexia nervosa restrictive type versus anorexia nervosa binge/purge type versus NED comparisons, along with corresponding pairwise comparisons, can be found in Appendix 1, Table S3. Although reduced n limits power, a 3-group ANOVA identified 9 differentially methylated probes (at \( Q < 0.01 \)). Among these were 3 probes related to the glutamate metabotropic receptor 2 (GRM2 [3 probes]). We also observed links to probes associated with genes that play a role in glia-neuron interactions (ICAM5, [5 probes]) and white-matter integrity/myelination (ASPA). Chronicity was also associated with the serotonin 2A receptor (HTR2A). Finally, the analysis isolated probes related to wound healing (TNXB), taste (TAS1R3), insulin metabolism (IRS2, RPTOR), skeletal homeostasis (LRP5) and age-related conditions (e.g., ELOVL2, HFL2). The direction of differences (on 39 of 64 [60.9%] differentially methylated probes) suggested a trend toward lower methylation in people with more chronic anorexia nervosa. Among identified genes, PRKT1, ZNRF2, RPTOR, NRXN2, SPTA1 and LRP5 were also isolated in the active versus remitted versus NED comparison described earlier.

**Pre-/post-treatment changes in methylation**

We found 73 probes (corresponding to 72 genes) at which the median change in BMI correlated with change in methylation at \( Q < 0.05 \) (and at \( Q < 0.01 \) on 8 probes; Appendix 1, Table S5). Differentially methylated probes included genes acting in cell growth (RPS6KA2), immune function (CLEC7A, IRAK3, TAP2, HHHLA2) and inflammatory responses (NFKBIA, NR1H3). Other probes were associated with genes implicated in olfaction (OR4C45), lipid metabolism (PEBP4, NR1H3), insulin function (IGF2R) and a nicotinic acetylcholine receptor (CHRNA5). One of the probes (corresponding to ASPA) was identified in the effects of chronicity described above. The direction of difference on 56 of 73 (76.7%) differentially methylated probes in the pre/post analysis showed that people who gained more weight during treatment tended to show larger increases in DNA methylation, implying that the direction of methylation-level changes associated with weight gain was opposite to that associated with chronic illness exposure. Among the identified genes, ESM1, GTC1, KLF39, EML6, RPS6KA2 and CLU1 were also identified in the active versus remitted versus NED comparison described earlier. Regressions examining associations with pre/post changes on the EDE-Q total or subscale scores yielded no significant results.

**Discussion**

We examined genome-wide methylation patterns in women with anorexia nervosa that was active or in stable remission, and in those who had no history of an eating disorder. In the active group, we also investigated methylation patterns as a function of chronicity of illness and treatment-linked changes in BMI and eating symptoms.
Group comparisons

Participants in the active and NED groups showed many differentially methylated sites, with significant between-group differences corresponding to genes implicated in metabolic and nutritional status (e.g., lipid, insulin and glucose metabolism), bone and tissue health, psychiatric status and immune function. At most differentially methylated probes, methylation levels were higher in the active group than the NED group, implying generally reduced expression of affected genes in actively ill participants. Comparisons between the active and remitted groups (the latter group presumed to represent susceptibility to anorexia nervosa in the absence of active illness sequelae) identified a parallel set of genes implicated in lipid, glucose and insulin metabolism; bone and tissue health; serotonin function; and immune function. Notably, the directional tendency of effects complemented that obtained in the active versus NED comparisons; that is, methylation levels on affected probes were generally lower in the remitted group than in the active group. Likewise, effects on probes that were common to active versus NED and active versus remitted comparisons pointed in opposite directions. Together, the pattern of results suggests methylation changes in people who are actively ill with anorexia nervosa — changes that can be “reset” by partial or full remission of illness. Similarly, findings that mainly differentiated people who were actively ill from those who were not currently ill (whether they had no eating disorder or were in remission from anorexia nervosa) leaned again toward the concept of DNA methylation being responsive to illness activity, rather than a stable, trait-like factor.

Correlational analyses

Consistent with the idea that many epigenetic changes constitute illness sequelae, longer exposure to active illness seemed to coincide with more marked methylation-level changes. Notably, the chronicity of illness was associated with methylation levels at genes associated with the functioning of 2 major neurotransmitters: glutamate and serotonin. Glutamate and serotonin systems have been implicated before in anorexia nervosa, and they are likely candidates underlying anorexia nervosa’s characteristic psychiatric manifestations. Moreover, findings isolated the serotonin-2A receptor gene (HTR2A), a gene modulating affect, cognition and emotion regulation, has been linked to anorexia nervosa in previous candidate-gene studies, and in our own previous epigenome-wide study.

Among the probes most strongly associated with illness duration, we found ELOVL2 and FHHL2, both of which have been associated with epigenetic age and age-related conditions. It is an intuitive point that the length of a person’s exposure to anorexia nervosa is likely to be detrimental to their health prospects, and our findings suggest that several adverse effects of this type may be epigenetically regulated. Consistent with possible effects of the underconsumption of nutrients implicated in DNA methylation, illness chronicity was inversely correlated with methylation levels at most of the implicated probes: greater duration of illness was associated with lower methylation. In contrast, longitudinal data indicated that BMI increases generally coincided with increases in methylation-level changes at genes associated with lipid and glucose metabolism, immune and inflammatory processes, and olfaction. Together, these results suggest that methylation levels may be responsive to short- and long-term alterations in illness status. If so, methylation measures could have promise as markers of illness staging.

We also want to comment on the possible disorder-specific relevance of differential methylation of 4 genes. We found that the presence and chronicity of illness was associated with methylation at probes related to the RPTOR gene, which influences cell growth in response to nutrients and insulin, and has been linked to such metabolic disorders as obesity and type 2 diabetes, and to the functioning of the gut microbiota. We also found active illness to be associated with increased methylation at probes associated with the PRKAG2 gene. Lower methylation of PRKAG2 has been associated with higher BMI in a community sample. In addition, similar to 2 previous studies in anorexia nervosa, we found that TNXB methylation was associated with the presence of anorexia nervosa; the 2 previous studies reported that methylation at this gene was altered in people with anorexia nervosa. TNXB has been involved in connective-tissue disorders. Furthermore, the observed decreases in NR1H3 methylation post-treatment was in line with the results of 2 studies showing hypermethylation of this gene in active anorexia nervosa.

Limitations

Given the tissue specificity of DNA methylation, brain tissue is the optimal medium for epigenetic studies on mental health entities. However, in the absence of postmortem brain banks for anorexia nervosa, studies such as ours must rely on biomaterials from peripheral tissues. Despite these limitations, however, epigenetic studies involving peripheral tissues can inform the understanding of processes in the brain. First, DNA methylation in the periphery may reflect a peripheral component of a body-wide somatic response to environmental signals that also alters methylation in the brain. Second, various blood–brain mediators (e.g., glucocorticoids, cytokines such as IL-1β) may link central and peripheral effects. Third, on certain genes, there are relatively good correspondences between epigenetic markings obtained in blood and brain. Finally, unique disease-relevant epigenetic markings in peripheral tissues, even if only partially representative of the effects in brain, may yet have clinical potential, especially in the case of a disorder such as anorexia nervosa, which has widespread effects throughout the body.

Without measures of gene expression, our results cannot ascertain the functional significance of the altered methylation levels we observed. However, the literature affirms that methylation levels correspond to expression
levels on many of the genes of interest found in this study, including HTR2A, ICAM5, CAMKK2, CCR7, ELOVL2 and FHL2. Future investigations (including in vitro models to establish direct influences of changes in DNA methylation on gene expression) may help elucidate the actual functional significance of the identified genes. Finally, some of our findings may have been influenced by the effects of medication or substance use. Future replication of findings will, therefore, be a determinant.

Conclusion

Our findings have associated anorexia nervosa with epigenetic alterations bearing upon individuals’ mental and physical status, metabolic functions and immunity, and also point to the likelihood (given that they tended to differentiate people with active anorexia nervosa from people in full or partial recovery from anorexia nervosa and from people without an eating disorder) that many of the alterations observed were reversible consequences of active illness. These findings are intriguing, because they may point to biomarkers for disease staging or targets for innovations in nutritional or pharmacological treatments.

Acknowledgements: The study was supported by a grant from the Canadian Institutes of Health Research (CIHR; MOP-142717) awarded to H. Steiger, L. Booij, L. Thaler, A. Labbe, R. Joob, M. Israël, M. Szyf, L. Agellon, L. Gauvin and A. St-Hilaire, and by a donation from Cogir Immobilier. L. Booij was supported by a CIHR New Investigator Award.

Affiliations: From the Eating Disorders Program, Douglas University Institute (Steiger, Kahan, Thaler, Fletcher, Israël, St-Hilaire, Rossi), the Research Centre, Douglas University Institute (Steiger, Kahan, Thaler, Fletcher, Joob, Israël, St-Hilaire, Rossi); the Department of Psychiatry, McGill University (Steiger, Booij, Thaler, Joob, Israël, St-Hilaire); the Department of Psychology, Concordia University (Booij); the Sainte-Justine Hospital Research Centre, University of Montreal (Booij); the Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (McGregor); the Department of Decision Sciences, HEC Montreal (Labbe); the Department of Pharmacology and Therapeutics, McGill University (Szyf); the School of Human Nutrition, McGill University (Agellon); and the Centre de recherche du Centre Hospitalier, de l’Université de Montréal (CRCHUM) (Gauvin), Montréal, Que., Canada.

Competing interests: A. Labbe and R. Joob are members of the journal editorial board; they were not involved in the evaluation or acceptance of this manuscript for publication. R. Joob reports clinician-scientist salary awards from Fonds de recherche du Québec outside the scope of this work. He participates on the advisory boards and speakers bureaus of Pfizer, Janssen Ortho, Otsuka, Lundbeck, Purdue and Myelin and has received honoraria from these companies. He also reports honoraria from Shire and royalties from Henry Stewart Talks. No other authors have declared competing interests.

Contributors: H. Steiger, L. Booij and M. Israël designed the study. H. Steiger, E. Kahan, L. Thaler, E. Fletcher, M. Israël, A. St-Hilaire and E. Rossi acquired the data, which H. Steiger, L. Booij, K. McGregor, A. Labbe, R. Joob, M. Szyf, L. Agellon and L. Gauvin analyzed. H. Steiger and L. Booij wrote the article, which all authors reviewed. All authors approved the final version to be published and can certify that no other individuals not listed as authors have made substantial contributions to the paper.

References


10. Steiger H, Thaler L. Eating disorders, gene-environment interac­
11. Szyf M. The dynamic epigenome and its implications in toxicol­
15. Mehta D, Kengel T, Comely KN, et al. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in post­
ticoid receptor gene promoter in bulimic women: associations with borderline personality disorder, suicidality, and exposure to child­
17. Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methyla­
A longitudinal, epigenome-wide study of DNA methylation in anorexia nervosa


